AhR inhibitor, use thereof, and preparation method therefor
The present disclosure relates to a compound having an AhR inhibitory effect as shown in FIG. (I), and a use thereof and a preparation method thereof.
1 . A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is selected from phenyl, pyridyl, pyrazolyl, wherein, the phenyl, pyridyl, or pyrazolyl is optionally substituted by one or two R 11 ;
R 11 is selected from fluoro, chloro, cyano, methyl, trifluoromethyl, or trifluoromethoxy;
R 2 is selected from phenyl, pyrazolyl, pyridyl, isoxazolyl, or pyrimidinyl, wherein, the phenyl, pyrazolyl, pyridyl, isoxazolyl, or pyrimidinyl is optionally substituted by one or two R 21 ;
R 21 is selected from fluoro, chloro, cyano, amino, methyl, methoxy, or cyclopropyl;
L is selected from single bond, —CH(CH 3 )—, —CH 2 CH 2 —, —CH(CH 2 CH 3 )—,
R 3 is selected from
2 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein:
-L-R 3 is selected from
3 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from
4 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is selected from
5 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from the group consisting of:
6 . The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the pharmaceutically acceptable salt is any or a combination of hydrochloride, hydrobromate, sulfate, phosphate, carbonate, acetate, propionate, methanesulfonate, lactate, benzenesulfonate, p-toluenesulfonate, succinate, maleate, fumarate, tartrate, citrate, or malate.
7 . A pharmaceutical composition, wherein the composition comprises the compound or pharmaceutically acceptable salt thereof according to claim 1 , or a pharmaceutically acceptable carrier.